[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-arteriosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-arteriosclerosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,92,125,154,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100066549","phase-2-fibroblast-growth-factor-1-fgf-1-for-the-treatment-of-coronary-heart-disease-100066549",false,"NCT00117936","Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease","Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study","Inclusion criteria\n\n1. Sign an informed consent form.\n2. Age ≥25 and ≤75 years, either gender, and any race.\n3. At least a 3 month history of chronic, stable angina and is relieved by rest and\u002For nitroglycerin.\n4. Documented symptomatic CCS Angina Classification of III to IV despite use of optimal medical therapy as noted in Inclusion Criterion 10.\n5. Pattern of CHD (coronary pathology) where percutaneous interventional therapy and\u002For CABG is not recommended by the treating cardiologist. This decision should have a documented basis in either complicated vessel physiology and\u002For lack of suitable target vessels for both PTCA and CABG, or past history of complications.\n6. One\u002Ftwo\u002Fthree vessel disease as evidenced either by an angiographic documentation of advanced atherosclerotic narrowing of ≥60% of at least one major epicardial coronary artery (right coronary artery \\[RCA\\], left circumflex \\[LCX\\], or LAD \\[or any of their branches\\]), or of diffuse type of CHD as evidenced by the appearance on coronary angiography of multiple stenoses, multiple atherosclerotic plaques, and\u002For peripheral occlusion(s) of coronary vessel(s) with and without a history of MIs.\n7. demonstrate a radionuclide or angiographically determined left ventricular ejection fraction (LVEF) ≥30%.\n8. Pre-operative proof of reversible ischemia.\n9. No evidence of proliferative retinopathy or significant non-proliferative retinopathy.\n10. must be on optimal medical therapy for at least 2 months prior to entering the study, as documented by a medical history. This will include medical management, and subjects must enter the study on at least one of the following medications: beta-blockers, calcium entry blockers, ranolizine, or long-acting nitrates.\n11. Exercise duration during the qualifying treadmill tests at Visit 1 and Visit 2 is ≥3 and ≤9 minutes on a modified Bruce protocol.\n12. Exercise durations for the qualifying treadmill tests at Visits 1 and 2 must satisfy at least one of the two following conditions: (a) they differ by less than or equal to 20% of the longer time; (b) they differ by less than or equal to 60 seconds. Subjects whose ETTs at Visits 1 and 2 do not satisfy at least one of these two conditions are allowed a third ETT, at the investigator's discretion, from 5 to 7 days after Visit 2. If a third ETT is done, then when compared with the second ETT it must satisfy at least one of the two conditions above.\n13. For a treadmill test result to support inclusion it must terminate in the presence of angina for either of the following reasons: (a) angina becomes too severe to continue the test AND there must be a horizontal depression or downsloping ST-segment of at least 1 mm measured 80 ms from the J point as subsequently established by the Biomedical Systems central ECG lab, or (b) angina of any grade AND there must be a horizontal depression or downsloping ST-segment measured 80 ms from the J point of 2 mm during exercise. The qualifying time for the treadmill test will then be the time to a horizontal depression or downsloping ST-segment of 1 mm compared to the pre-exercise ST segment as subsequently established by the Biomedical Systems central ECG lab.\n14. A forced vital capacity (FVC) of ≥30%.\n15. A negative pregnancy test in women of childbearing potential at Screening.\n16. Female subjects must be post-menopausal or sterilized, or if she is of childbearing potential, she is not breast feeding, has no intention to become pregnant during the course of the study, and is using contraceptive drugs or devices.\n17. Negative cancer screening tests according to the American Cancer Society (\\[ACS\\] Appendix 13.8).\n18. Ability to complete the study in compliance with the protocol.\n\nExclusion criteria\n\n1. History of undergoing a CABG, PTCA or TMR or evidence of an acute MI in the last 3 months.\n2. Subjects with malignancies or a history of malignancies (with the exception of basal cell carcinoma \\[BCC\\] of the skin) will be excluded from the study. Those subjects with a history of BCC are eligible for enrollment, and will be monitored by a qualified dermatologist every 8 weeks for a period of 6 months for evaluation of their skin condition. Subjects with existing BCC will be excluded from the study.\n3. Evidence of concurrent clinically significant infection (e.g. elevated white blood cell \\[WBC\\] count \\>13,000 x 109\u002FL, temperature \\>38.5°C), evidence of \"common cold\" or \"flu.\"\n4. Concomitant other structural heart disease, such as moderate to severe heart valve disease, congenital heart disease, etc. other than evidence of congestive heart failure that is directly related to past ischemic events.\n5. Left ventricular thrombus (mobile or mural-based) as evidenced by ventriculogram or echocardiography.\n6. Creatine kinase (CK) levels \\>3 x upper limit of normal (ULN).\n7. Renal insufficiency requiring dialysis or laboratory evidence of a serum creatinine \\>2.0 mg\u002FdL.\n8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2 x ULN.\n9. History of coagulation disorders or abnormal prothrombin time (PT) or partial thromboplastin time (PTT) \\>1.5 x ULN, thrombocytopenia (\\\u003C100,000\u002Fµl), or ongoing anticoagulant therapy (with the exception of aspirin, up to 85 mg\u002Fday).\n10. History of blood cell diseases.\n11. Poorly controlled insulin-dependent diabetes mellitus (HbA1c \\>8%)\n12. Pre-existing retinal disease, including proliferative retinopathy, severe nonproliferative retinopathy.\n13. Use of any illicit recreational drugs within the past year.\n14. A positive test result for human immunodeficiency virus (HIV) antibody.\n15. Screening ECG results demonstrating recent evidence of transmural ischemia.\n16. Clinically significant ECG abnormalities, e.g.: QRS duration \\>0.12 seconds; QTc \\>450 ms in males or \\>460 ms in females;High-grade trioventricular (AV) block; Left bundle branch block(LBBB; Left ventricular hypertrophy(LVH) with secondary ST-T changes; Frequent, recurrent, or sustained ventricular arrhythmia; Resting ST segment depression \\>1 mm (measured 80 ms beyond the J point) at baseline.\n17. Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.\n18. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent and comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the trial.\n19. Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving IMP.\n20. Any subject with unstable angina.\n21. Heart failure New York Heart Association (NYHA) Functional Class III or IV.\n22. Uncontrolled hypertension precluding exercise testing and\u002For contributing to angina severity (systolic blood pressure \\[SBP\\] \\>200 mmHg or diastolic blood pressure \\[DBP\\] \\>110 mmHg), or significant hypotension (SBP \\\u003C90 mmHg or DBP \\\u003C60 mmHg).\n23. Subjects currently on External Counter Pulsation therapy or who have received this therapy within 3 months prior to the screening date.\n24. Any mobility or pulmonary complication that impedes the subject's ability to perform an exercise stress test.\n25. Total fasting serum cholesterol \\>200 mg\u002FdL (if levels greater than or equal to 200 mg\u002FdL, additional medical interventions can be initiated to bring levels below 200 mg\u002FdL).\n26. History of heparin-induced thrombocytopenia.\n27. Subjects with a history of recurrent symptomatic atrial fibrillation or significant ventricular arrhythmias.\n28. Aortic or mitral valve replacement.\n29. Subjects who have undergone heart transplantation.\n30. Medical history and physical examination displaying any evidence that catheterization is contraindicated.","ALL","25 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping catheters, to stimulate the growth of blood vessels around blocked coronary arteries.",[27,28,29,30],"Coronary Disease","Coronary Heart Disease","Myocardial Ischemia","Coronary Arteriosclerosis",[32,33,34,35,36,37],"Angiogenesis","No-option heart patients","Blocked coronary artery","Revascularization","FGF-1","growth factor","NOT_YET_RECRUITING","2026-08-17",{"date":41,"type":42},"2026-08-19","ACTUAL",{"date":44,"type":21},"2027-09-01",{"date":46,"type":21},"2030-06-15",{"name":48,"class":49},"Venturis Therapeutics, Inc.","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100570032","effects-of-a-healthy-nordic-diet-on-atherosclerosis-in-patients-with-coronary-heart-disease-100570032","NCT06701968","Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease","A Healthy Nordic Diet to Reduce the Progression of Atherosclerosis in Individuals with Coronary Heart Disease: a Secondary Prevention Trial","NORDHEART","Inclusion Criteria:\n\n* Men and women\n* Diagnosis with MI from 2 weeks after diagnosis and with maximum 6 months after diagnosis\n* Diagnosis with CCS (e.g. stable angina pectoris)\n* Ages 50 to 80 years\n* BMI 25-40.\n\nExclusion Criteria:\n\n* Severe heart failure (NYHA classes III, IV)\n* Alcohol intake \\>20g\u002Fday\n* Unwillingness to follow a new prescribed diet for 18 months\n* Other diseases implying a short estimated life expectancy (e.g. severe malignant or kidney or liver disease, as judged by consenting physician).","50 Years","80 Years",{"count":20,"type":21},[62],"NA","Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear. The investigators will investigate if a healthy Nordic diet (HND) reduces plaque volume, coronary artery calcification (CAC), and plaque inflammation (FAI) in CHD, and examine if changes in gut microbiota may be linked to plaque progression over time. The investigators will also explore if the diet response can be predicted by the metabolic phenotype.\n\nIn total 150 CHD patients is randomized to a HND rich in unsaturated fat and fibre from plants, or to a \"usual care diet\" for 18 months. Plaque volume and composition is assessed by CT, and fecal microbiota composition is determined by deep metagenome shotgun sequencing. CHD and metabolic risk factors, liver fat, muscle fat and biomarkers of diet adherence (plasma fatty acids, whole-grain metabolites) are measured. Machine-learning is used to identify diet \"responders\" on plaque progression, based on the individual microbiome and metabolome.\n\nIf a HND reduces plaque progression, this would be novel information of clinical importance. Also, if the diet alters microbiota that are linked to plaque progression, this would be of high scientific interest. Finally, potential prediction of the diet-response would open up for more personalized treatment of atherosclerosis.",[27,30,65,66,67,68],"Myocardial Infarction","Chronic Coronary Syndrome","MASLD","Type 2 Diabetes",[70,71,72,73,74,75,76,77,78,79],"Diet","Secondary prevention","Coronary plaque regression","Atherosclerosis","Type 2 diabetes","Coronary heart disease","Myocardial infarction","Coronary computed tomography angiography","Healthy nordic diet","NAFLD","RECRUITING","2025-03-05",{"date":83,"type":42},"2025-03-06",{"date":85,"type":21},"2025-03-20",{"date":87,"type":21},"2031-12-30",{"name":89,"class":90},"Uppsala University","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":103,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100577160","progression-of-atheroma-evaluated-by-ct-angiography-and-intracoronary-imaging-techniques-100577160","NCT06794684","PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques","Evaluation of Atherosclerotic Plaque Progression by Coronary Computed Tomography Angiography and Intracoronary Imaging Techniques in Patients With Coronary Artery Disease","PRACTICE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically significant angina pectoris, or suspected CAD\n* Receive coronary CTA scan, with a visible plaque (defined as ≥25% diameter stenosis) in major coronary arteries.\n\nExclusion Criteria:\n\n* Unsuitable for coronary CTA (such as severe renal impairment, uncontrolled thyroid condition, allergic to iodine, etc.)\n* Receive percutaneous coronary intervention (PCI) within 6 months\n* Prior history of myocardial infarction or heart failure\n* Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\n* Abnormal liver function (serum alanine aminotransferase \\[ALT\\] level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR ≤30 ml\u002Fmin)\n* Familial hypercholesterolemia\n* Estimated survival ≤ 1 year\n* Malignant tumor\n* Pregnant or lactation, or have the intention to give birth within one year\n* Poor coordinance, unable to follow-up","18 Years",{"count":102,"type":21},50000,"2 Years","OBSERVATIONAL","This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted after 2 years. Comprehensive morphological and functional plaque analysis will be performed. The impact of these morphological and functional parameters, alongside cardiometabolic factors and pharmacological treatments on plaque progression and the occurrence of major adverse cardiovascular events (MACEs) will be analyzed. In addition, intracoronary imaging techniques will be used to improve the accuracy of plaque analysis by coronary CTA.",[107,30],"Coronary Arterial Disease (CAD)",[109,110,111,112,113,114],"Coronary CTA","Plaque Progression","coronary artery disease","high-risk plaques","plaque composition","intracoronary imaging","2025-01-21",{"date":117,"type":42},"2025-01-27",{"date":119,"type":42},"2016-01-01",{"date":121,"type":21},"2030-05-31",{"name":123,"class":90},"Ruijin Hospital",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":132,"targetDuration":134,"studyType":104,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":91},"100521900","complex-registry---a-prospective-cohort-study-to-describe-the-management-and-outcomes-of-patients-presenting-with-complex-and-calcified-coronary-artery-disease-100521900","NCT06075602","COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","COMPLEX","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals presenting with chronic, complex and\u002For calcified CAD and requiring PCI or CABG\n* Complex coronary artery disease \u002F lesions must include at least one of the following attributes:\n* Long and\u002F or heavily calcified coronary lesions\n* In-stent restenosis\n* Chronic total occlusions (CTO)\n* Left main lesions\n* Bifurcation lesions\n* Bypass graft lesions\n* Small vessel disease \u002F coronary microvascular dysfunction (e.g. not amenable to PCI)\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the patient.\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* Patients with no complex and calcified CAD",{"count":133,"type":21},5000,"10 Years","The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and\u002F or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques\u002F devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[27,137,138,30,139,140,141,142,143,144],"Coronary Artery Disease","Coronary Restenosis","Coronary Artery Calcification","Stable Chronic Angina","Angina Pectoris","Angina, Stable","Angina, Unstable","Stent Thrombosis","2024-10-27",{"date":147,"type":42},"2024-10-29",{"date":149,"type":42},"2021-11-01",{"date":151,"type":21},"2031-12-31",{"name":153,"class":90},"Luzerner Kantonsspital",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":161,"targetDuration":134,"studyType":104,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":91},"100438392","siroop-registry---a-prospective-registry-study-to-evaluate-the-outcomes-of-coronary-artery-disease-patients-treated-with-sirolimus-or-paclitaxel-eluting-balloon-catheters-100438392","NCT04988685","SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","SIROOP","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI\n* Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* pregnancy and lactation\n* Indication for surgical revascularization",{"count":162,"type":21},2000,"The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[27,137,138,30,139,140,141,142,143,144],{"date":147,"type":42},{"date":167,"type":42},"2021-06-01",{"date":151,"type":21},{"name":153,"class":90},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":177,"targetDuration":134,"studyType":104,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":91},"100426002","clinical-utility-and-outcome-prediction-of-cardiovascular-computed-tomography-predict-ct-100426002","NCT04827316","Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)","PREDICT-CT","Inclusion Criteria:\n\n* Adult individual \\>18 years\n* Undergoing clinically indicated CCTA\n* Signed informed consent or waiver\n\nExclusion Criteria:\n\n* None",{"count":178,"type":21},4200,"In this study the investigators retrospectively and prospectively collect information from enrolled subjects undergoing CCTA and evaluate the association of cardiac and non-cardiac imaging with laboratory markers and clinical data including outcome.",[137,30,181],"Coronary; Ischemic",[183],"Cardiovascular Computed Tomography","2024-10-16",{"date":186,"type":42},"2024-10-18",{"date":188,"type":42},"2017-06-01",{"date":190,"type":21},"2031-02-01",{"name":192,"class":90},"Insel Gruppe AG, University Hospital Bern"]